Hi Chiragjain,
It seems you have too many stocks in your PF, not sure if you're able to review the performance of all the Stocks and keep track of the Corporate Actions.
Suggest if you can trim to a manageable limit.
Thanks

This looks like a no brainer stock, with everything going right for the stock and company

1. Q1 result was superb as 70 % inc in profit, all four quarters are expected to be like this good.
2. RBI rate cutting will further increase the profitability with NCD/CP financing increasing qoq
3. NIMs will further improve as year passes by, cost of funds decreasing
4. Stock is still illiquid and under owned/undiscovered to some extent by institutions
5. Any fund getting in will lead to further rerating
6. A growth of 30/35 % in itself is a huge growth with NIL NPA
7. RBI reducing risk wt for housing loans will further help. Avg ticket size of 18 lakh is another positive.

Disc : invested

@pikrohit ... In my mental model the EPS of 30 for FY16 is given (though we can't take anything for granted till it actually gets reported ), what I will be looking on EPS front is that how far on north or south of 40 they will end up, the Q2 results should be able to give a good idea about this.

What is working in favor of both Alembic and Torrent now is that they were slow and probably late to make entry into US and historically their US business has been small and that has set up a small base. e.g. US revenue of torrent were 134 MUSD and Alembic had international generic (inc US) revenue of 80 M USD for FY15. Now revenue from single molecule (Abilify) in FY16 will most likely exceed their entire full year FY15 revenue from US generic and will give a big swing to both topline and even more bigger swing to bottomline as contribution to bottomline will be much higher due to lesser price erosion in Abilify because of limited competition compared to a normal generic. On top of abilify we will have Detrol and probably Nexium for Torrent and Celebrex for Alembic plus a robust base business from India and other molecules from international generics.
At a molecule level abilify is a one off opportunity but at the company level both Alembic and Torrent have good product pipeline which can provide similar upside giving decent overall CAGR even after considering abilify effect.
Another company in similar situation is Cipla where a single molecule (Nexium) in US has provided a huge upswing to both top line and bottomline (despite Cipla having a much bigger size) as is evident from Q1 results.

Income group Monthly expenditure on housing Est. no. of household Housing shortage Share of shortage
( Rs ) ( million ) ( million ) ( % )
Economically weak 0 - 3300 17.5 17.20 98.2
Lower income group 3301 -7300 27.5 1.50 5.4
Middle income group 7301 - 14500 9.9 0.04 0.2
Higher income group  14500 7 - -
Source : Report of technical group ( 12th 5 year plan ) on housing shortage

Above table shows the shortage of affortable housing and represents the enormous opportunity present and everybody has space to grow.

But instead of growth by new companies what would be important that which HFC's is able to maintain its asset quality.

Obtaining market share at the cost of assest quality is not advisable.

As well said by warren Buffet ' When the tide turn off then you come to know who is sailing naked '

For Gruh finance the LTV ( loan to value ) is 65% - 75% max. which shows the conservative mindset of the management and margin of safety in case of default, while incase of the HFC LTV is generally 85%.

For last 5 years for Gruh FY10-FY14 gross NPA's has come down from 1.11% to 0.27%.

While for Repco for June FY14 the gross NPA was 2.5%.